NO328116B1 - Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom. - Google Patents

Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom. Download PDF

Info

Publication number: NO328116B1
Authority: NO; Norway
Prior art keywords: ltp; antibody; receptor; cells; tnf
Prior art date: 1998-01-30

Application number

NO20003848A

Other languages

English (en)

Norwegian (no)

Other versions

NO20003848L (no

NO20003848D0 (no

Inventor

Jeffrey L Browning

Jeanette Thorbecke

Vincent Tsiagbe

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-30

Filing date

2000-07-27

Publication date

2009-12-14

2000-07-27 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2000-07-27 Publication of NO20003848D0 publication Critical patent/NO20003848D0/no

2000-10-02 Publication of NO20003848L publication Critical patent/NO20003848L/no

2009-12-14 Publication of NO328116B1 publication Critical patent/NO328116B1/no

Links

239000003112 inhibitor Substances 0.000 title claims abstract description 14
201000003444 follicular lymphoma Diseases 0.000 title claims abstract description 13
238000002360 preparation method Methods 0.000 title claims description 5
108090000362 Lymphotoxin-beta Proteins 0.000 title claims description 4
239000008194 pharmaceutical composition Substances 0.000 title claims description 4
102000003959 Lymphotoxin-beta Human genes 0.000 title 1
230000037361 pathway Effects 0.000 claims abstract description 25
206010028980 Neoplasm Diseases 0.000 claims abstract description 21
239000003446 ligand Substances 0.000 claims description 30
238000011282 treatment Methods 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 25
230000000694 effects Effects 0.000 claims description 17
230000003993 interaction Effects 0.000 claims description 12
108020001756 ligand binding domains Proteins 0.000 claims description 10
108060003951 Immunoglobulin Proteins 0.000 claims description 8
102000018358 immunoglobulin Human genes 0.000 claims description 8
108010029697 CD40 Ligand Proteins 0.000 claims description 4
102100032937 CD40 ligand Human genes 0.000 claims description 4
102100026894 Lymphotoxin-beta Human genes 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 3
239000002246 antineoplastic agent Substances 0.000 claims description 3
229940127089 cytotoxic agent Drugs 0.000 claims description 3
230000005855 radiation Effects 0.000 claims description 3
238000010322 bone marrow transplantation Methods 0.000 claims description 2
102100040247 Tumor necrosis factor Human genes 0.000 claims 3
108090000542 Lymphotoxin-alpha Proteins 0.000 abstract description 11
102000004083 Lymphotoxin-alpha Human genes 0.000 abstract description 6
230000001225 therapeutic effect Effects 0.000 abstract description 4
210000004027 cell Anatomy 0.000 description 41
102000005962 receptors Human genes 0.000 description 40
108020003175 receptors Proteins 0.000 description 40
239000000427 antigen Substances 0.000 description 33
102000036639 antigens Human genes 0.000 description 33
108091007433 antigens Proteins 0.000 description 33
102000003390 tumor necrosis factor Human genes 0.000 description 26
108060008682 Tumor Necrosis Factor Proteins 0.000 description 22
239000002981 blocking agent Substances 0.000 description 22
150000001875 compounds Chemical class 0.000 description 20
210000003719 b-lymphocyte Anatomy 0.000 description 19
102000037865 fusion proteins Human genes 0.000 description 18
108020001507 fusion proteins Proteins 0.000 description 18
238000000034 method Methods 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
210000000285 follicular dendritic cell Anatomy 0.000 description 16
101150073396 LTA gene Proteins 0.000 description 15
241001465754 Metazoa Species 0.000 description 15
210000001165 lymph node Anatomy 0.000 description 13
101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 12
206010025323 Lymphomas Diseases 0.000 description 12
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 12
210000000952 spleen Anatomy 0.000 description 11
210000001744 T-lymphocyte Anatomy 0.000 description 10
230000018109 developmental process Effects 0.000 description 9
230000011664 signaling Effects 0.000 description 9
102000004127 Cytokines Human genes 0.000 description 8
108090000695 Cytokines Proteins 0.000 description 8
238000011161 development Methods 0.000 description 8
210000001280 germinal center Anatomy 0.000 description 8
108020004511 Recombinant DNA Proteins 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000003393 splenic effect Effects 0.000 description 7
230000002950 deficient Effects 0.000 description 6
230000006870 function Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
102100026238 Lymphotoxin-alpha Human genes 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000004927 fusion Effects 0.000 description 5
230000028993 immune response Effects 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
101150013553 CD40 gene Proteins 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000012636 effector Substances 0.000 description 4
230000012010 growth Effects 0.000 description 4
210000002443 helper t lymphocyte Anatomy 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
230000009466 transformation Effects 0.000 description 4
238000002054 transplantation Methods 0.000 description 4
-1 LTp Proteins 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000011254 conventional chemotherapy Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
210000001102 germinal center b cell Anatomy 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000006187 pill Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000004044 response Effects 0.000 description 3
210000005212 secondary lymphoid organ Anatomy 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
102000009109 Fc receptors Human genes 0.000 description 2
108010087819 Fc receptors Proteins 0.000 description 2
101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 2
102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 2
241000700159 Rattus Species 0.000 description 2
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000004154 complement system Effects 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000003325 follicular Effects 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000009851 immunogenic response Effects 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003902 lesion Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000003563 lymphoid tissue Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000037452 priming Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
239000013598 vector Substances 0.000 description 2
108010082808 4-1BB Ligand Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
108010046080 CD27 Ligand Proteins 0.000 description 1
102100027207 CD27 antigen Human genes 0.000 description 1
102100025221 CD70 antigen Human genes 0.000 description 1
101100024001 Caenorhabditis elegans moma-1 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
208000024781 Immune Complex disease Diseases 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
108010042215 OX40 Ligand Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010033737 Pokeweed Mitogens Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
208000007660 Residual Neoplasm Diseases 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
210000004241 Th2 cell Anatomy 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000000961 alloantigen Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000008321 arterial blood flow Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
230000012178 germinal center formation Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000007188 immune regulating pathway Effects 0.000 description 1
230000003832 immune regulation Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
230000005296 lymph node development Effects 0.000 description 1
208000019420 lymphoid neoplasm Diseases 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
210000003826 marginal zone b cell Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
210000000274 microglia Anatomy 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000005305 organ development Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229940071643 prefilled syringe Drugs 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000004647 pro-inflammatory pathway Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000002633 protecting effect Effects 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
238000009666 routine test Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
208000025883 type III hypersensitivity disease Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C07K14/5255—Lymphotoxin [LT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C07K16/242—Lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20003848A 1998-01-30 2000-07-27 Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom. NO328116B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7311298P	1998-01-30	1998-01-30
US7341098P	1998-02-02	1998-02-02
PCT/US1999/001928 WO1999038525A1 (en)	1998-01-30	1999-01-29	Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway

Publications (3)

Publication Number	Publication Date
NO20003848D0 NO20003848D0 (no)	2000-07-27
NO20003848L NO20003848L (no)	2000-10-02
NO328116B1 true NO328116B1 (no)	2009-12-14

Family

ID=26754147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20003848A NO328116B1 (no)	1998-01-30	2000-07-27	Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom.

Country Status (24)

Country	Link
EP (1)	EP1051187B9 (is)
JP (2)	JP4713733B2 (is)
KR (1)	KR100622960B1 (is)
CN (1)	CN1287853C (is)
AT (1)	ATE253930T1 (is)
AU (1)	AU752710B2 (is)
BR (1)	BR9908214A (is)
CA (1)	CA2319698A1 (is)
CZ (1)	CZ301026B6 (is)
DE (1)	DE69912743T2 (is)
DK (1)	DK1051187T3 (is)
EA (1)	EA003862B1 (is)
EE (1)	EE05235B1 (is)
ES (1)	ES2211035T3 (is)
HU (1)	HU226044B1 (is)
IL (2)	IL137489A0 (is)
IS (1)	IS2254B (is)
NO (1)	NO328116B1 (is)
NZ (1)	NZ506529A (is)
PL (1)	PL203279B1 (is)
PT (1)	PT1051187E (is)
SK (1)	SK285725B6 (is)
TR (2)	TR200101693T2 (is)
WO (1)	WO1999038525A1 (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2313893T3 (es) *	1999-06-28	2009-03-16	ABBOTT GMBH & CO. KG	Composicion para la prevencion de crecimiento tumoral.
WO2001058953A2 (en) *	2000-02-11	2001-08-16	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
NZ525793A (en)	2000-10-13	2008-04-30	Biogen Idec Inc	Humanized anti-LT-beta-R antibodies
US7456219B2 (en)	2002-03-04	2008-11-25	Merck Hdac Research, Llc	Polymorphs of suberoylanilide hydroxamic acid
PL372239A1 (en)	2002-03-04	2005-07-11	Aton Pharma, Inc.	Methods of inducing terminal differentiation
TW200416044A (en)	2002-07-01	2004-09-01	Biogen Inc	Humanized anti-lymphotoxin β receptor antibodies
WO2004016317A1 (en) *	2002-08-14	2004-02-26	Erasmus University Medical Center Rotterdam	Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
JP2006508645A (ja) *	2002-08-14	2006-03-16	エラスムスユニバーシティメディカルセンターロッテルダム	抗癌剤の開発および癌の診断のための、腫瘍の発生に関与することが同定されたマウスゲノム領域の使用
EP1641827A2 (en)	2003-06-27	2006-04-05	Biogen Idec MA Inc.	Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
NZ550518A (en)	2004-03-23	2009-11-27	Biogen Idec Inc	Agents that cross link TNF receptors for treating cancer
WO2006074399A2 (en)	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) *	2006-05-17	2014-11-26	上海复旦张江生物医药股份有限公司	淋巴毒素在制备增加化疗药物敏感性的药物中的应用
EP2073833A2 (en)	2006-10-20	2009-07-01	Biogen Idec MA Inc.	Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747023A (en) *	1994-07-01	1998-05-05	Genentech, Inc.	Cancer therapy using lymphotoxin
US5925351A (en) *	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) *	1997-04-25	1998-10-25	Takeda Chemical Industries, Ltd.	Novel receptor protein and its use

1999
- 1999-01-29 IL IL13748999A patent/IL137489A0/xx unknown
- 1999-01-29 HU HU0102363A patent/HU226044B1/hu not_active IP Right Cessation
- 1999-01-29 CA CA002319698A patent/CA2319698A1/en not_active Abandoned
- 1999-01-29 WO PCT/US1999/001928 patent/WO1999038525A1/en not_active Ceased
- 1999-01-29 KR KR1020007008353A patent/KR100622960B1/ko not_active Expired - Fee Related
- 1999-01-29 AT AT99903480T patent/ATE253930T1/de active
- 1999-01-29 PL PL342063A patent/PL203279B1/pl unknown
- 1999-01-29 TR TR2001/01693T patent/TR200101693T2/xx unknown
- 1999-01-29 DK DK99903480T patent/DK1051187T3/da active
- 1999-01-29 CN CNB998024902A patent/CN1287853C/zh not_active Expired - Fee Related
- 1999-01-29 DE DE69912743T patent/DE69912743T2/de not_active Expired - Lifetime
- 1999-01-29 JP JP2000529257A patent/JP4713733B2/ja not_active Expired - Fee Related
- 1999-01-29 CZ CZ20002751A patent/CZ301026B6/cs not_active IP Right Cessation
- 1999-01-29 ES ES99903480T patent/ES2211035T3/es not_active Expired - Lifetime
- 1999-01-29 TR TR2000/02203T patent/TR200002203T2/xx unknown
- 1999-01-29 AU AU23488/99A patent/AU752710B2/en not_active Ceased
- 1999-01-29 PT PT99903480T patent/PT1051187E/pt unknown
- 1999-01-29 BR BR9908214-4A patent/BR9908214A/pt not_active IP Right Cessation
- 1999-01-29 EA EA200000798A patent/EA003862B1/ru not_active IP Right Cessation
- 1999-01-29 SK SK1130-2000A patent/SK285725B6/sk not_active IP Right Cessation
- 1999-01-29 EP EP99903480A patent/EP1051187B9/en not_active Expired - Lifetime
- 1999-01-29 EE EEP200000446A patent/EE05235B1/xx not_active IP Right Cessation
- 1999-01-29 NZ NZ506529A patent/NZ506529A/xx not_active IP Right Cessation
2000
- 2000-07-21 IS IS5570A patent/IS2254B/is unknown
- 2000-07-25 IL IL137489A patent/IL137489A/en not_active IP Right Cessation
- 2000-07-27 NO NO20003848A patent/NO328116B1/no not_active IP Right Cessation
2010
- 2010-06-22 JP JP2010142108A patent/JP2010235621A/ja active Pending

Also Published As

Publication number	Publication date
PL203279B1 (pl)	2009-09-30
NZ506529A (en)	2002-12-20
HU226044B1 (en)	2008-03-28
IL137489A0 (en)	2001-07-24
EA003862B1 (ru)	2003-10-30
EP1051187B9 (en)	2004-08-11
CZ20002751A3 (cs)	2000-12-13
DK1051187T3 (da)	2004-03-08
DE69912743T2 (de)	2004-09-23
DE69912743D1 (de)	2003-12-18
IS5570A (is)	2000-07-21
SK11302000A3 (sk)	2001-01-18
BR9908214A (pt)	2000-11-28
WO1999038525A1 (en)	1999-08-05
EA200000798A1 (ru)	2001-02-26
NO20003848L (no)	2000-10-02
EP1051187B1 (en)	2003-11-12
HUP0102363A3 (en)	2004-04-28
KR20010040497A (ko)	2001-05-15
AU752710B2 (en)	2002-09-26
CN1289252A (zh)	2001-03-28
IL137489A (en)	2010-05-31
TR200101693T2 (tr)	2002-06-21
CZ301026B6 (cs)	2009-10-14
ATE253930T1 (de)	2003-11-15
CN1287853C (zh)	2006-12-06
TR200002203T2 (tr)	2000-12-21
CA2319698A1 (en)	1999-08-05
ES2211035T3 (es)	2004-07-01
IS2254B (is)	2007-06-15
JP4713733B2 (ja)	2011-06-29
SK285725B6 (sk)	2007-07-06
JP2002501902A (ja)	2002-01-22
HUP0102363A2 (hu)	2001-10-28
HK1029944A1 (en)	2001-04-20
AU2348899A (en)	1999-08-16
EP1051187A1 (en)	2000-11-15
EE05235B1 (et)	2009-12-15
EE200000446A (et)	2001-08-15
KR100622960B1 (ko)	2006-09-12
PT1051187E (pt)	2004-03-31
NO20003848D0 (no)	2000-07-27
PL342063A1 (en)	2001-05-21
JP2010235621A (ja)	2010-10-21

Publication	Publication Date	Title
US8142779B2 (en)	2012-03-27	Treatment of follicular lymphomas using inhibitors of the LT pathway
JP2010235621A (ja)	2010-10-21	リンホトキシン（ｌｔ）経路のインヒビターを使用する濾胞性リンパ腫の処置
US6284236B1 (en)	2001-09-04	Cytokine that induces apoptosis
JP6919091B2 (ja)	2021-08-18	Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用
US20110123551A1 (en)	2011-05-26	Hvem/btla, hvem/cd 160 and hvem/gd cis complexes and methods of use
US20020039577A1 (en)	2002-04-04	Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
NO321707B1 (no)	2006-06-26	Isolert DNA som koder for et TRAIL-polypeptid og et opploselig TRAIL-polypeptid, ekspresjonsvektor, fremgangsmate for fremstilling av et TRAIL-polypeptid, isolert DNA som koder for et fusjonsprotein, fremgangsmate for fremstilling av en TRAIL-oligomer, antistoff som binder et TRAIL-polypeptid, renset TRAIL-polypeptid og opploselig TRAIL-polypeptid, oligomer, farmasoytisk preparat, farmasoytisk preparat for bruk som et medikament, farmasoytisk preparat for anvendelse ved indusering av apoptose hos malceller samt anvendelse av et TRAIL-polypeptid ved fremstilling av et medikament.
NO331410B1 (no)	2011-12-19	Antistoff mot BAFF-reseptor (BCMA) som et immunoregulatorisk middel
US20030223989A1 (en)	2003-12-04	CD137 agonists to treat patients with IgE-mediated conditions
JP2002509431A (ja)	2002-03-26	ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
CA3138111A1 (en)	2010-03-04	Method and compositions for enhanced anti-tumor effector functioning of t cells
JP2022532249A (ja)	2022-07-13	インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法
NO326967B1 (no)	2009-03-23	Tumornekrosefaktor-relatert ligand (TRELL), rekombinant DNA som koder for TRELL, farmasøytiske sammensetninger inneholdende slike, samt antistoff spesifikt reaktivt med TRELL
Holler et al.	2000	Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors
HK1029944B (en)	2004-04-02	Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
MXPA97010399A (es)	1998-10-15	Citocina que induce apoptosis

Legal Events

Date	Code	Title	Description
2015-08-24	MM1K	Lapsed by not paying the annual fees